Northern Institute for Cancer Research

Staff Profile

Dr Mojgan Reza

Research Associate


I am a Cell- and Molecular Biologist specialising in "non-genotoxic combination treatments for paediatric acute myeloid leukaemia (AML)". After several years of working in diagnostics and research in Neuromuscular Diseases in University Hospital in Essen, Germany and Institute of Genetic Medicine in Newcastle, UK, I took a different route and moved to the Northern Institute for Cancer Research to pursue my research in leukaemia (since Oct 2017).

Academic background

  • PhD in Medical Genetics, Newcastle University

Areas of expertise

  • Cell- and Molecular biology
  • Leukemia
  • Genetics
  • Muscular Dystrophy
  • Management
  • Biobank

Google scholar: Click here.


The mainstream treatments for AML have not changed much for decades and the mechanisms underlying drug resistance in this type of blood cancer are poorly understood. To identify additional therapeutic targets in paediatric setting, I am carrying out genome wide CRISPR-Cas9 screens followed by next generation sequencing to identify mutants resistant to the CDK4/6 inhibitors in human AML cancer cell lines. We wish to identify a series of mutations that result in CDK4/6 inhibitor resistance which should be investigated as a therapeutic strategy in AML and provide a large number of genetic vulnerabilities that can be targeted in downstream studies. My project is funded by "Children with Cancer UK".


Supervising UG and Mres students